Serenex Inc announced the signing of a research agreement with Eli Lilly & Company. The agreement involves the utilization of Serenex's novel chemoproteomics technologies within selected Lilly drug discovery programs. The companies will evaluate how these technologies may impact the process of identifying the best compounds to advance to drug development.

The agreement provides Lilly with access to Serenex's unique Proteome Mining and Functional Proteome Fractionation technologies to screen Lilly compounds against thousands of protein targets, from multiple proteomes, simultaneously and in a single step. These proprietary processes may help to quickly provide previously unobtainable compound/target binding information, potentially improving the quality and timeliness of decisions about the development of drug candidates.

Richard S. Kent, president and chief executive officer of Serenex, said, "We believe our technology significantly improves the drug discovery and development process. Serenex provides higher quality information more rapidly to its partners than provided by standard discovery approaches. We are excited about the opportunity to work with key scientists at Eli Lilly and pleased to apply our technologies to their research programs."